If you have been reading about Translational gap and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
=== Carbon methylation === Radical SAM methylases/methyltransferases are one of the largest yet diverse subgroups and are capable of methylating a broad range of unreactive carbon and phosphorus centers. These enzymes are divided into three classes (Class A, B and C) with representative methylation mechanisms. The shared characteristic is the usage of SAM, split into two distinct roles: one as a source of a methyl group donor, and the second as a source of 5'-dAdo radical. Another class has been proposed (class D) but proved to be wrongly assigned.
Octopuses offer many possibilities in biological research; the California two-spot octopus had its genome sequenced, allowing exploration of its molecular adaptations. Having independently evolved mammal-like intelligence, octopuses were compared by the philosopher Peter Godfrey-Smith, who studied the nature of intelligence, to hypothetical intelligent extraterrestrials. Their intelligence and flexible bodies enable them to escape from supposedly secure tanks in public aquariums. Due to their intelligence, many argue that octopuses should be given protections when used for experiments. In the UK from 1993 to 2012, the common octopus (Octopus vulgaris) was the only invertebrate protected under the Animals (Scientific Procedures) Act 1986. In 2012, this legislation was extended to include all cephalopods in accordance with a general EU directive. Some robotics research is exploring biomimicry of octopus features. Octopus arms can move and sense largely autonomously without intervention from the animal's central nervous system. In 2015 a team in Italy built soft-bodied robots able to crawl and swim, requiring only minimal computation. In 2017, a German company made an arm with a soft pneumatically controlled silicone gripper fitted with two rows of suckers. It was able to grasp objects such as a metal tube, a magazine, or a ball, and to fill a glass by pouring water from a bottle.
In the 2011–12 season, a coaching change by appointing Christian Streich, with the club finishing 12th. Under Christian Streich, the 2012–13 Bundesliga season saw the club finish in fifth place, their best league standing since 1994–95. The fifth-place finish secured a position in the 2013–14 UEFA Europa League. Had Freiburg defeated Schalke 04 on the final matchday of the season, Freiburg would have advanced further in the league table against Schalke and qualified for the UEFA Champions League for the first time in club history. The 1–2 defeat to Schalke, however, saw Schalke secure fourth place in the league and qualify for the tournament instead. During the 2012–13 season, Freiburg also advanced to the semi-finals of the DFB-Pokal for the first time in the club's history, but lost to local rivals VfB Stuttgart 1–2, and missed the chance to play Bayern Munich in the final. In the 2014–15 season, after six years in the top flight, Freiburg was relegated to the 2. Bundesliga by a single point after a final-day defeat at Hannover 96. This was despite beating Bayern Munich in the second-last game. In the following season, however, the club earned its fifth promotion to the Bundesliga, with two matches to spare. The first season back in the Bundesliga saw them end seventh. This saw Freiburg qualify for the Europa League, as German cupwinners Borussia Dortmund were already qualified for the Champions League. The side were eliminated in the third qualification round against NK Domžale from Slovenia. Freiburg stayed in the top flight, finishing 15th.
Sources: en.wikipedia.org
Radioactive decay (also known as nuclear decay, radioactivity, radioactive disintegration, or nuclear disintegration) is the process by which an unstable atomic nucleus loses energy by radiation. A material containing unstable nuclei is considered radioactive. Three of the most common types of decay are alpha, beta, and gamma decay. The weak force is the mechanism that is responsible for beta decay, while the other two are governed by the electromagnetic and nuclear forces. Radioactive decay is a random process at the level of single atoms. According to quantum theory, it is impossible to predict when a particular atom will decay, regardless of how long the atom has existed. However, for a significant number of identical atoms, the overall decay rate can be expressed as a decay constant or as a half-life. The half-lives of radioactive isotopes have a huge range: from nearly instantaneous to far longer than the age of the universe. The decaying nucleus is called the parent radionuclide (or parent radioisotope), and the process produces at least one daughter nuclide. Except for gamma decay or internal conversion from a nuclear excited state, the decay is a nuclear transmutation resulting in a daughter containing a different number of protons or neutrons (or both). When the number of protons changes, an atom of a different chemical element is created. There are 28 naturally occurring chemical elements on Earth that are radioactive, consisting of 35 radionuclides (seven elements have two different radionuclides each) that date before the time of formation of the Solar System.
Main reactor Ethylene oxide scrubber Ethylene oxide de-sorber Stripping and distillation column CO2 scrubber and CO2 de-scrubber Main Reactor: The main reactor consists of thousands of catalyst tubes in bundles. These tubes are generally 6 to 15 m (20 to 50 ft) long with an inner diameter of 20 to 50 mm (0.8 to 2.0 in). The catalyst packed in these tubes is in the form of spheres or rings of diameter 3 to 10 mm (0.12 to 0.39 in). The operating conditions of 200–300 °C (390–570 °F) with a pressure of 1–3 MPa (150–440 psi) prevail in the reactor. To maintain this temperature, the cooling system of the reactor plays a vital role. With the aging of the catalyst, its selectivity decreases and it produces more exothermic side products of CO2. Ethylene oxide scrubber: After the gaseous stream from the main reactor, containing ethylene oxide (1–2%) and CO2 (5%), is cooled, it is then passed to the ethylene oxide scrubber. Here, water is used as the scrubbing media which scrubs away majority of ethylene oxide along with some amounts of CO2, N2, CH2=CH2, CH4 and aldehydes (introduced by the recycle stream). Also, a small proportion of the gas leaving the ethylene oxide scrubber (0.1–0.2%) is removed continuously (combusted) to prevent the buildup of inert compounds (N2, Ar, and C2H6), which are introduced as impurities with the reactants. Ethylene oxide de-sorber: The aqueous stream resulting from the above scrubbing process is then sent to the ethylene oxide de-sorber.
The company opened new offices in Singapore and Hong Kong in 1927 and in Taiwan in 1929 to distribute its product throughout Southeast Asia. Between 1920 and 1929, revenue from the seasoning's sales rose from nearly 3 million yen to 10 million yen, largely due to increased exports of the product to foreign markets. To lower the cost of mass production, the seasoning's wheat was replaced with soybeans, as the price of the latter at the time was lower than the former's. In the United States, the seasoning, labeled by the FDA as a "Vegetable Protein Derivative", sold poorly on the consumer market, but Ajinomoto expanded their operations in the United States in 1931 due to mass orders of the seasoning by H.J. Heinz, Co. and Campbell Soup Co. Between 1931 and 1937, seasoning production increased from 1,077 tons to 3,750 tons, with revenue rising from 13 million yen to 27 million yen. Due to Japan's increasing isolationism in the late 1930s, the production of AJI-NO-MOTO decreased from 3,750 tons in 1937 to 2,339 tons in 1940. By 1942, production of the seasoning was reduced to 1,000 tons before completely stopping by 1944 due to World War II.
=== Enzyme-mediated (biological) === Enzyme-mediated (biological) chiral inversion of organic compounds is caused by highly chiral endogenous molecules found in receptors, enzymes, and other structures. While enzyme inhibitors suppress enzyme activity, enzyme inducers boost enzyme concentration and activity. The primary determinants of inter-individual variability in drug metabolism in humans are thought to include genetic polymorphism and a variety of other variables, including age, gender, biological conditions, pregnancy, illnesses, stress, nutrition, and drugs. For instance, Reichel et al. reported that a 2-arylpropionyl-coenzyme-A epimerase was molecularly cloned and expressed as a crucial enzyme in the inversion metabolism of ibuprofen. Ibuprofen's chiral inversion by enzymes has been documented in humans.
Sources: en.wikipedia.org
Congenital hypofibrinogenemia is a rare inherited disorder in which blood may not clot normally due to reduced levels of fibrinogen (plasma fibrinogen typically <150 but >50 mg/dl). The disorder reflects a disruptive mutation in only one of the two parental FGA, FGB, or FBG genes and has a low degree of genetic penetrance, i.e. only some family members with the defective gene ever exhibit symptoms. Symptoms of the disorder, which more often occurs in individuals with lower plasma fibrinogen levels, include episodic bleeding and thrombosis that typically begin in late childhood or adulthood.
Brenner has developed targeted, quantitative analysis of the NAD+ metabolome and made fundamental contributions to NAD metabolism including discovery of nicotinic acid riboside-dependent NAD synthesis, elucidating the mechanism of synthesis of nicotinic acid adenine dinucleotide phosphate, and discovering multiple conditions in which NAD metabolism is dysregulated in disease. Brenner is active in translating NR technologies to treat and prevent human conditions that disturb the NAD system including cancer diabetic and chemotherapeutic peripheral neuropathy, heart failure, central brain injury, inflammation, mitochondrial myopathy pellagra, and infections such as coronavirus infection Brenner's work included the first human trial of NR in 2016, which demonstrated safe oral availability as an NAD+ precursor, thereby creating the foundational intellectual property for the NAD boosting industry. Though Brenner was the first to show that NR increases SIR2 activity, improves gene silencing, and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs inflammatory conditions and metabolic stresses that dysregulate NAD+ and NADPH.
=== Membrane protein databases === TCDB - Transporter Classification database, a comprehensive classification of transmembrane transporter proteins Orientations of Proteins in Membranes (OPM) database - 3D structures of integral and peripheral membrane proteins arranged in the lipid bilayer Protein Data Bank of Transmembrane Proteins - 3D models of transmembrane proteins approximately arranged in the lipid bilayer. TransportDB - Genomics-oriented database of transporters from TIGR Membrane PDB Archived 2020-08-03 at the Wayback Machine - Database of 3D structures of integral membrane proteins and hydrophobic peptides with an emphasis on crystallization conditions Mpstruc database Archived 2013-12-25 at the Wayback Machine - A curated list of selected transmembrane proteins from the Protein Data Bank MemProtMD - a database of membrane protein structures simulated by coarse-grained molecular dynamics Membranome database provides information about bitopic proteins from several model organisms
Oscillation Repetitive rhythmic activity in neurons or neural networks. Neural oscillations, such as alpha waves and gamma waves, are observed in brain activity recordings. Otolith organs Structures in the vestibular system (the utricle and saccule) that detect linear acceleration and head position relative to gravity.
== Personal life == Findlay was married to lawyer A. Boyd Ferris, with whom she had two children. After Ferris died from a heart attack in 1989, she met actor Brent Chapman. The two married in 1993 and had two more daughters together; they also have nine grandchildren. Chapman was elected as the provincial MLA for Surrey South in the 2024 British Columbia general election. Findlay is a member of the All-Saints Community Church in White Rock, British Columbia, which is part of the Anglican Mission in the Americas, through its Canadian branch. Findlay's volunteer posts, in addition to the Canadian Bar Association, have included chair of the Vancouver City Planning Commission, board member of Science World, executive member of the Junior Leagues of Canada, president of Delta Zeta chapter of Alpha Gamma Delta International Fraternity, and honorary counsel for the Chinese Benevolent Association of Canada. In 2016, she was named a Distinguished Citizen by Alpha Gamma Delta. In 2001, she declared bankruptcy with more than a half million dollars in debt. She attributed the bankruptcy to a legal battle with the Musqueam First Nation.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.